<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719912</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 01-2015</org_study_id>
    <nct_id>NCT02719912</nct_id>
  </id_info>
  <brief_title>Mitral Valve Replacement With MValve Dock and Lotus</brief_title>
  <acronym>DOCK 1</acronym>
  <official_title>Mitral Valve Replacement With the MValve Dock and A Percutaneous Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MValve Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MValve Technologies Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the MValve mitral prosthesis in conjunction with a Lotus transcatheter&#xD;
      heart valve (THV) for mitral valve replacement in subjects at high risk for conventional&#xD;
      mitral valve replacement or repair surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective first in man feasibility study intended to evaluate preliminary&#xD;
      safety and effectiveness of the MValve Mitral Dock with Lotus transcatheter heart valve for&#xD;
      mitral valve replacement in subjects who are at high risk for surgical valve repair or&#xD;
      replacement.&#xD;
&#xD;
      The surgical technique adapts the valve-in-valve approach for mitral replacement in&#xD;
      degenerated mitral prostheses to failing native mitral valves. The MValve Dock is designed to&#xD;
      provide a structural platform within the mitral annulus so that the Lotus THV can be&#xD;
      implanted in a secure fashion in the mitral annulus. The investigational device anchors to&#xD;
      the mitral annulus commissures, sparing the native valve leaflets and sub annular apparatus.&#xD;
      This study is designed to treat subjects with moderate-to-severe MR who are not deemed&#xD;
      candidates for mitral valve surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite serious adverse cardiac events and stroke</measure>
    <time_frame>30 days</time_frame>
    <description>death, myocardial infarction, stroke, repeat surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation grade</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Valve Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitral valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mitral valve replacement</intervention_name>
    <description>transcatheter mitral valve replacement</description>
    <arm_group_label>Valve Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic ≥3+ degenerative or functional mitral regurgitation of either ischemic or&#xD;
             non-ischemic etiology based by a qualifying echocardiography obtained within 90 days&#xD;
             prior to the procedure.&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Class III or IV.&#xD;
&#xD;
          -  High risk for conventional open mitral valve repair or replacement surgery in the&#xD;
             consideration of the site Heart Team.&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) is ≥30% within 30 days prior to the&#xD;
             procedure.&#xD;
&#xD;
          -  Mitral valve annular commissure to commissure (C/C) dimension between 30-35 mm by&#xD;
             echocardiography.&#xD;
&#xD;
          -  Left atrial diameter &lt;5.5 cm by echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior mitral valve replacement or repair surgery.&#xD;
&#xD;
          -  Prior transapical surgery.&#xD;
&#xD;
          -  Severe aortic or tricuspid valve disease. - Severe symptomatic carotid stenosis (&gt;70%&#xD;
             by ultrasound).&#xD;
&#xD;
          -  ACC/AHA Stage D heart failure.&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology.&#xD;
&#xD;
          -  Infiltrative cardiomyopathies (amyloidosis, hemochromatosis, sarcoidosis).&#xD;
&#xD;
          -  Physical evidence of right-sided congestive heart failure with echocardiographic&#xD;
             evidence of moderate or severe right ventricular dysfunction.&#xD;
&#xD;
          -  Severe mitral annular calcification.&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &lt; 30.&#xD;
&#xD;
          -  Hemodynamic instability defined as systolic pressure &lt; 90 mm Hg with or without&#xD;
             afterload reduction, cardiogenic shock, or the need for inotropic support or&#xD;
             intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart&#xD;
             assistance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dante Pazzenese Institute of Cardiology</name>
      <address>
        <city>Sau Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander Abizaid, MD</last_name>
    </contact>
    <contact_backup>
      <email>aabizaid@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Abizaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frederic Petit</last_name>
      <email>fpetit@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Didier Tchetche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bonn - Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Kaja Twelker, MD</last_name>
      <email>kaja.twelker@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Poznan</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Maciej Lesiak, MD</last_name>
    </contact>
    <contact_backup>
      <email>maciej.lesiak@skpp.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Maciej Lesiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

